Next-generation NK cell and innate lymphoid cell therapeutics using macrocyclic multi-specific cell engagers that redirect NK cytotoxicity for precision killing. Initial focus on activating the innate immune system in solid tumor microenvironments to enhance cancer cell killing and improve outcomes in oncology and autoimmune indications.